How Fast Do Lung Nodules Grow If Cancerous?

Most cancerous lung nodules double in volume roughly every four to eight months, though the range is enormous depending on the type of cancer, the nodule’s appearance on imaging, and the tumor’s molecular makeup. A large meta-analysis of primary lung cancers found that solid malignant nodules had a pooled mean volume doubling time of about 207 days, while part-solid and pure ground-glass cancers grew far more slowly, averaging 536 and 669 days respectively.¹ Those numbers, though, hide a wide spread that matters for anyone trying to understand what a follow-up CT scan means.

How Growth Is Actually Measured

Doctors track nodule growth using a concept called volume doubling time, or VDT. Rather than measuring how quickly a nodule adds millimeters to its diameter, VDT captures how long it takes the entire three-dimensional volume to double. This distinction matters because a nodule only needs to grow about 26 percent in diameter to double in volume. A change that looks modest on a flat CT image can represent a meaningful jump in tumor bulk.

European lung screening programs have increasingly moved toward semi-automated volume measurements on CT, which tend to be more accurate and reproducible than traditional diameter-based approaches.² In everyday clinical practice, though, many radiologists still rely on two-dimensional diameter measurements, and the two methods can yield different impressions of how fast something is changing. If you are comparing scans done at different facilities or with different software, the measured “growth” can vary even when the nodule itself hasn’t changed much.

How Cancer Type Changes the Speed

Not all lung cancers grow at the same pace. The histological subtype, meaning what the cancer cells look like under a microscope, is one of the strongest predictors of how fast a nodule enlarges. The same meta-analysis that reported an overall mean VDT of 207 days for solid cancers broke the numbers down further: adenocarcinoma averaged about 223 days, squamous cell carcinoma about 140 days, and small cell lung cancer roughly 73 days.¹ An older study using chest radiograph screening found broadly similar patterns, with adenocarcinoma averaging 177 days and squamous cell carcinoma averaging 133 days.³

Small cell lung cancer stands apart. With a doubling time measured in weeks rather than months, it can transform from a small nodule to a sizable mass in a timeframe that catches patients off guard. This is one reason small cell cancers are often diagnosed at a more advanced stage. Meanwhile, adenocarcinoma, the most common lung cancer overall, occupies a wide middle ground. Some adenocarcinomas are indolent and grow over years; others are aggressive and double in volume in under 100 days.

In a lung cancer screening study comparing malignant and benign nodules, growing solid cancers had a median VDT of 204 days, and the vast majority (about 92 percent) doubled in volume in under 400 days.⁴ But that same study found that well over half of growing benign nodules also doubled within 400 days, which is a reminder that growth speed alone cannot reliably separate cancer from something harmless.

Ground-Glass and Part-Solid Nodules Grow Much More Slowly

If your CT report describes a nodule as a “ground-glass opacity” or “part-solid,” the growth calculus changes dramatically. These hazy, cloud-like nodules represent a different biology from dense solid nodules, and they tend to enlarge at a fraction of the speed. A study of ground-glass nodule lung adenocarcinomas found a median volume doubling time of about 1,059 days, which is nearly three years.⁵ The meta-analysis cited earlier reported a mean VDT of 669 days for nonsolid lung cancers and 536 days for part-solid ones.¹

This slow pace creates a clinical puzzle. A ground-glass nodule that is technically cancerous may sit on a CT scan for years without meaningful change, then eventually start to grow or develop a solid component. One study tracked pure ground-glass nodules that had been stable for a full decade and found that about 4 percent eventually grew after that long period of quiescence, suggesting that follow-up beyond 10 years may sometimes be needed.⁶ Early-stage adenocarcinomas in ground-glass nodules frequently had doubling times exceeding one year in older studies as well.⁷

Research into why some of these nodules eventually transition from indolent to progressive points to changes in the tumor’s immediate environment. One study found that immune cells called SPP1-positive macrophages accumulate at the edges of mixed ground-glass nodules and may block other immune cells from penetrating the tumor core, potentially enabling the shift toward malignancy.⁸

Indolent Cancers and the Overdiagnosis Problem

The existence of very slow-growing lung cancers creates a real dilemma for screening programs. If a CT scan detects a tumor that would never have caused symptoms or shortened someone’s life, treating it still exposes the patient to the risks of surgery, radiation, or chemotherapy. This is the overdiagnosis problem, and it is not trivial. The meta-analysis on lung cancer growth rates found that roughly 35 percent of screen-detected lung cancers were indolent, with adenocarcinoma accounting for the majority of those slow-growers.¹

A systematic review of overdiagnosis in low-dose CT screening quantified the issue directly. Early estimates suggested overdiagnosis rates as high as 37 percent of screen-detected cancers, but with longer follow-up (more than five years), those estimates dropped to around 7 percent.⁹ That decline makes sense: some “overdiagnosed” cancers eventually do grow and become clinically relevant if you wait long enough. But the finding reinforces that a substantial minority of cancers found on screening are genuinely slow enough that the patient would have died of something else first.

What Screening Guidelines Consider “Growth”

Growth definitions matter because they determine when a radiologist flags a nodule for further workup versus recommending continued surveillance. The ACR’s Lung-RADS system, widely used in U.S. lung cancer screening, defines growth as an increase in mean diameter of more than 1.5 millimeters within a 12-month interval.¹⁰ Earlier versions of Lung-RADS did not specify a time interval, which caused inconsistency in how growth was assessed across different practices.

For incidentally discovered nodules (those found on a CT done for some other reason, like a scan after a car accident), the Fleischner Society guidelines take a slightly different approach. They set follow-up recommendations based on nodule size, number, and the patient’s risk factors like smoking history, aiming to limit further evaluation when the two-year probability of cancer is below one percent.¹¹ In practice, this means very small nodules (under 6 millimeters) in low-risk patients often need no follow-up at all, while larger nodules or those in smokers get serial CT scans at intervals designed to catch growth that would suggest cancer.

The 1.5-millimeter threshold can feel arbitrary, but it reflects real measurement limitations. CT scans have inherent variability: the same nodule measured twice on the same machine can differ by a millimeter or so depending on how the patient breathes, how the software draws its boundaries, and where in the breathing cycle the scan was acquired. Setting the bar at 1.5 millimeters helps avoid flagging measurement noise as true growth.

When Fast Growth Isn’t Cancer

A rapidly growing lung nodule is alarming, but not every fast-growing nodule turns out to be malignant. Infections, particularly fungal infections and tuberculosis, are the most common benign mimics of lung cancer on imaging. They can form nodules that grow, develop spiculated (spiky) borders, and even light up on PET scans, all features typically associated with cancer.¹²

Occupational and environmental exposures can also fool clinicians. In one case report, a former glassblower presented with a lung nodule that grew from 13 millimeters to 23 millimeters in six months, with a doubling time of about 186 days and imaging features strongly suggesting cancer. After surgery, pathology revealed it was a foreign-body reaction to inhaled glass fragments, not a tumor at all.¹³ The screening study comparing malignant and benign nodules found that more than half of growing benign nodules had doubling times under 400 days, overlapping significantly with the cancerous range.⁴ Growth speed, taken alone, is not a reliable way to tell cancer from non-cancer. It has to be interpreted alongside imaging features, patient history, and sometimes biopsy.

Genetic Mutations and Growth Speed

The molecular characteristics of a tumor influence its doubling time as much as its cell type does. One of the clearest examples involves EGFR mutations, which are common in lung adenocarcinoma, especially in non-smokers and in East Asian populations. A study of non-small-cell lung cancer patients found that those with EGFR mutations had a median doubling time of 676 days, compared to 139 days in patients without the mutation.¹⁴ That is a nearly fivefold difference, meaning an EGFR-mutant cancer might take close to two years to double while a wild-type cancer of the same histology doubles in under five months.

This has practical consequences. EGFR-mutant tumors tend to behave less aggressively, at least initially, and often respond well to targeted therapies. But the slow growth can also mean that the nodule sits at a size below biopsy thresholds for longer, delaying diagnosis. A separate study identified smoking history, higher CT density values, and deep lobulation (a jagged, irregular border) as risk factors for rapid nodule growth in solid non-small-cell lung cancers.¹⁵ These features help clinicians estimate which nodules are likely to outpace routine surveillance intervals.

PET Scans and Metabolic Activity

PET scans measure how metabolically active a nodule is by tracking how avidly it takes up a radioactive sugar tracer. Higher metabolic activity generally correlates with faster growth, but the relationship is not perfectly linear across all cancer types. A study comparing PET uptake with volume doubling times found a statistically significant link between higher metabolic activity and faster growth for adenocarcinomas specifically, but no significant correlation for squamous cell carcinomas.¹⁶

This matters because squamous cell cancers tend to be highly PET-avid regardless of their growth rate, while some slow-growing adenocarcinomas, particularly ground-glass types, may show little or no PET uptake despite being cancerous. A PET scan that “lights up” strongly should raise concern, but a scan that is only mildly positive or negative does not rule out a slowly progressive malignancy.

Why Delays in Diagnosis Can Be Costly

For fast-growing cancers, the timeline between detection and treatment can meaningfully affect outcomes. A modeling study used real-world data from major lung cancer databases to estimate what happens when diagnostic workup is delayed for a 20-millimeter tumor with a fast doubling time (60 days). Lung-cancer-specific five-year survival dropped from about 83 percent with prompt treatment to roughly 77 percent after a 90-day delay, about 67 percent after a 180-day delay, and around 32 percent after a one-year delay.¹⁷ Even for tumors with a moderate doubling time of 120 days, a 180-day delay reduced cure rates by 7 to 8 percentage points across different databases.

These numbers put the growth-rate question into stark human terms. A nodule doubling every two months is not an emergency that requires action within hours, but letting it drift for six months while waiting for another follow-up scan can allow a curable stage I cancer to progress to a stage where outcomes are markedly worse. This is one argument for more aggressive workup of nodules with imaging features suggestive of rapid growth.

Lung Metastases from Other Cancers

Not every cancerous nodule in the lung is a primary lung cancer. The lungs are one of the most common sites for metastases from cancers originating elsewhere, and these metastatic nodules follow their own growth kinetics. In patients with bone and soft-tissue sarcomas, pulmonary metastases that grew quickly (median doubling time of 56 days) were strongly associated with the development of new metastatic deposits after surgical removal, compared to slower-growing ones (median 140 days).¹⁸

Interestingly, lung metastases from thyroid cancer showed remarkably constant growth rates over a median follow-up of 8.5 years, suggesting that the biological clock of these particular metastases ticks at a steady pace rather than accelerating over time.¹⁹ This steady-state growth is clinically useful because it means early doubling time measurements can reliably predict future behavior, helping oncologists decide when to start systemic therapy.

AI Models for Predicting Nodule Growth

One of the frustrations with traditional nodule surveillance is that it requires waiting and rescanning. You discover a nodule, scan again in three to six months, and only then learn whether it has grown. Researchers are now developing AI-based tools that attempt to predict growth from a single CT scan, before any follow-up imaging exists. A recent fusion model combining radiomics (extracting quantitative features from the image) with deep learning achieved strong performance in predicting which nodules would grow, with an area under the curve of 0.90 and balanced sensitivity and specificity around 82 to 84 percent.²⁰

These tools are not yet standard clinical practice, and an area under the curve of 0.90, while impressive, means the model still gets a meaningful fraction of cases wrong. But the trajectory is clear: future nodule management will likely incorporate AI risk stratification to help decide which patients need urgent workup, which can safely wait longer between scans, and which can potentially avoid follow-up imaging altogether. For patients living with the anxiety of a “watch and wait” nodule, these tools cannot arrive soon enough.

1
European Journal of Cancer. Systematic review and meta-analysis of primary lung cancer growth rate quantified by volume doubling time through computed tomography measurement
2
Europe PMC. Volume versus diameter assessment of small pulmonary nodules in CT lung cancer screening
3
Europe PMC. Volume doubling time of lung cancers detected in a chest radiograph mass screening program: Comparison with CT screening
4
PubMed Central. Volume Doubling Times of Benign and Malignant Nodules in Lung Cancer Screening
5
PubMed Central. Relationships between growth rate and Ki-67 and immune indices in ground-glass nodule-featured lung adenocarcinoma
6
Elsevier. The Growth of Screening-Detected Pure Ground-Glass Nodules Following 10 Years of Stability
7
American Journal of Roentgenology. Evolution of peripheral lung adenocarcinomas: CT findings correlated with histology and tumor doubling time
8
PubMed Central. Senescent SPP1(+) macrophages remodel the tumor microenvironment and promote the progression of early-stage lung adenocarcinoma featured with mixed ground glass nodule
9
Wiley Online Library. Overdiagnosis in low-dose CT lung cancer screening: A systematic review and meta-analysis of overall magnitude and subgroup variations
10
Elsevier / Journal of the American College of Radiology. ACR Lung-RADS v2022: Assessment Categories and Management Recommendations
11
Elsevier / Journal of the American College of Radiology. Fleischner Society Guideline Recommendations for Incidentally Detected Pulmonary Nodules and the Probability of Lung Cancer
12
ScienceDirect. Infections that mimic malignancy in the lung
13
PubMed Central. A solitary pulmonary nodule in a former glass blower mimicking a primary lung adenocarcinoma
14
PubMed Central. Epidermal growth factor receptor mutations: effect on volume doubling time of non-small-cell lung cancer patients
15
AME Publishing Company. Influencing factors and prediction of growth heterogeneity in solid nodule non-small cell lung cancer based on artificial intelligence: a prospective study
16
Elsevier. PET standardized uptake values of primary lung cancer for comparison with tumor volume doubling times
17
RSNA. Impact on Prognosis of Stage I Non-Small Cell Lung Cancer Secondary to Delays in Diagnostic Workup
18
American Roentgen Ray Society (AJR) / PubMed Central. Volume Doubling Times of Pulmonary Metastases in Patients With Bone and Soft-Tissue Sarcomas: Associations With Subsequent New Metastases and Survival After Metastasectomy
19
PubMed Central. Tumor volume doubling time of the pulmonary metastases predicts overall survival and can guide the initiation of multi-kinase inhibitor therapy in metastatic follicular cell derived thyroid carcinoma
20
AME Publishing Company. Predicting pulmonary nodule growth from a single time point: a fusion model of radiomics and deep learning to optimize follow-up strategies